Mifepristone, a drug approved in the United States for abortion for more than 25 years, has also been shown in multiple international studies to effectively treat uterine fibroids and endometriosis. However, ongoing political efforts to restrict access to the medication are limiting its availability for these non-abortion indications, according to medical researchers and patient advocates. While the drug is prescribed for these conditions in countries such as China and India, regulatory and political barriers in the U.S. have prevented widespread adoption of mifepristone as a standard treatment for women’s health issues beyond pregnancy termination.
The debate centers on whether the political framing of mifepristone as primarily an abortion drug has created unnecessary hurdles for patients suffering from fibroids and endometriosis, conditions that affect a significant portion of the female population. Uterine fibroids are non-cancerous growths in the uterus that can cause severe pain, bleeding, and infertility. Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus. Both conditions often lead to invasive surgical interventions, such as hysterectomies, due to a lack of widely available non-invasive pharmaceutical options in the United States.
What the Left Is Saying
Medical professionals and progressive advocates argue that restricting mifepristone based on its abortion applications ignores its proven efficacy in treating other serious health conditions. Dr. Abby Liberty, an OB-GYN and researcher at Oregon Health and Science University, stated that the United States is being "left behind" in women's health innovation due to "red tape" and the political framing of these medicines. She noted that abortion stigma directly limits access to and investment in mifepristone as a potential treatment option for fibroids.
Patient advocates emphasize the human cost of these restrictions. Danielle Shoback, a 36-year-old endometriosis patient from Jersey City, described spending over 20 years suffering from debilitating periods and chronic fatigue without a clear diagnosis. After researching clinical trials in China, she found evidence that mifepristone reduced bleeding and pain associated with endometriosis. Although local doctors initially dismissed her request to try the drug off-label, she eventually accessed it through a telemedicine service. "It definitely changed my life a lot, maybe saved my life," Shoback said, noting that she had been missing half of her life due to the severity of her symptoms.
Dr. Rebecca Gomperts, a Dutch physician and researcher who has worked to improve access to abortion medication globally, characterized the restrictions as a form of gender discrimination. "It will take away very valid treatment options for complaints and diseases that only women have, and thus it will increase disease burden. It will increase mortality among women, for sure," Gomperts stated. She pointed to Europe as an example where institutions are more resilient to political pressure, allowing for broader use of these medications for various health conditions.
What the Right Is Saying
Conservative and anti-abortion groups maintain that mifepristone is fundamentally an abortion medication and express skepticism about its safety and effectiveness for non-abortion conditions. Representative Chris Smith (R-NJ) has publicly referred to mifepristone as "baby poison," reflecting the view held by many in the anti-abortion movement that the drug's primary function is to terminate pregnancies. These groups argue that the medical evidence supporting its use for fibroids and endometriosis is insufficient to justify expanding its availability or removing existing restrictions.
Recent political actions have focused on tightening regulations around these drugs. The Trump administration launched a review of mifepristone earlier this year, signaling continued federal scrutiny. At the state level, Louisiana made the drug a controlled substance two years ago, and currently, Louisiana, Texas, and Florida are involved in legal efforts to further restrict access. Proponents of these measures argue that strict controls are necessary to ensure the drug is not misused and to uphold moral objections to abortion.
Advocates for these restrictions contend that the push to repurpose mifepristone for other conditions is a strategy to bypass abortion restrictions. They argue that if the drug were approved specifically for fibroids or endometriosis, it might face different regulatory hurdles. By keeping the focus on its abortion application, they aim to limit its overall availability in the United States, regardless of its potential utility in other medical contexts.
What the Numbers Show
Mifepristone has been used safely by more than 7.5 million American women since its approval for abortion in the United States over 25 years ago. Uterine fibroids are extremely common, affecting approximately 70 percent of white women and more than 80 percent of Black women by the age of 50. Despite this high prevalence, the average time it takes for women to receive treatment for fibroids is more than three years, often due to diagnostic delays and limited treatment options.
International studies cited by researchers indicate that mifepristone and similar drugs can shrink uterine fibroids by up to 50 percent. In countries like China and India, physicians already prescribe these medications for patients with fibroids and endometriosis. The mechanism of action involves blocking the hormone progesterone, which stops the signal for fibroid growth and may alter the tissue around the fibroids to facilitate shrinkage. Dr. Liberty noted that smaller fibroids lead to quicker recovery times and smaller incisions during any necessary surgeries, reducing overall health risks.
The current standard of care in the U.S. often involves invasive procedures, with hysterectomy being the most common surgical intervention for severe cases. The inability to easily access non-invasive pharmacological treatments like mifepristone contributes to the reliance on surgery. Data from patient experiences, such as those of Deja Cradle and Danielle Shoback, highlight the prolonged periods of misdiagnosis and suffering that can occur before effective treatment is found. Cradle, for instance, waited nearly 20 years after her first period to receive a proper diagnosis for her condition.
The Bottom Line
The intersection of reproductive politics and general women’s health policy is creating a gap in medical care for conditions like fibroids and endometriosis. While mifepristone has a long safety record and proven efficacy in international studies for non-abortion conditions, its classification and regulation in the United States remain heavily influenced by the abortion debate. This has resulted in limited access for patients who could benefit from non-invasive treatments, often forcing them to seek off-label use through telemedicine or endure prolonged suffering and invasive surgeries.
As anti-abortion groups continue to lobby for further restrictions, the future of mifepristone as a general women’s health medication remains uncertain. Researchers argue that the political framing of the drug is hindering medical progress and investment in alternative treatments. Patients like Deja Cradle are calling for increased awareness to drive policy change, comparing the current struggle to historical civil rights movements. The outcome of ongoing legal challenges and federal reviews will likely determine whether U.S. women can access mifepristone for its broader medical potential or if it will remain primarily an abortion medication with limited secondary applications.